
Robert J. Warden
Examiner (ID: 7352)
| Most Active Art Unit | 1306 |
| Art Unit(s) | 1306, 1312, 1305, 1802, 1744, 1791, 1207, 1742, 1801, 1302, 1208 |
| Total Applications | 342 |
| Issued Applications | 259 |
| Pending Applications | 11 |
| Abandoned Applications | 72 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16915691
[patent_doc_number] => 20210188783
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => SUBSTITUTED BENZIMIDAZOLES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA KINASE
[patent_app_type] => utility
[patent_app_number] => 17/181497
[patent_app_country] => US
[patent_app_date] => 2021-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28589
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -59
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181497
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/181497 | Substituted benzimidazoles as inhibitors of transforming growth factor-b kinase | Feb 21, 2021 | Issued |
Array
(
[id] => 19826265
[patent_doc_number] => 12247030
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-11
[patent_title] => Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine
[patent_app_type] => utility
[patent_app_number] => 17/176914
[patent_app_country] => US
[patent_app_date] => 2021-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56654
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 520
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176914
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/176914 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | Feb 15, 2021 | Issued |
Array
(
[id] => 17022259
[patent_doc_number] => 20210246130
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA
[patent_app_type] => utility
[patent_app_number] => 17/173826
[patent_app_country] => US
[patent_app_date] => 2021-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26988
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 153
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17173826
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/173826 | DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | Feb 10, 2021 | Abandoned |
Array
(
[id] => 18685135
[patent_doc_number] => 11780852
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-10
[patent_title] => Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
[patent_app_type] => utility
[patent_app_number] => 17/248832
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 25742
[patent_no_of_claims] => 55
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17248832
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/248832 | Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | Feb 9, 2021 | Issued |
Array
(
[id] => 17005344
[patent_doc_number] => 20210236505
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/171061
[patent_app_country] => US
[patent_app_date] => 2021-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16394
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17171061
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/171061 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | Feb 8, 2021 | Abandoned |
Array
(
[id] => 18348774
[patent_doc_number] => 20230136885
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/798690
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5356
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17798690
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/798690 | Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives for treating autoimmune diseases | Feb 4, 2021 | Issued |
Array
(
[id] => 17036623
[patent_doc_number] => 20210253581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/168399
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6161
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17168399
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/168399 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of interferon signaling | Feb 4, 2021 | Issued |
Array
(
[id] => 18363233
[patent_doc_number] => 20230144824
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/793248
[patent_app_country] => US
[patent_app_date] => 2021-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43147
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793248
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793248 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Jan 25, 2021 | Abandoned |
Array
(
[id] => 18739528
[patent_doc_number] => 20230348468
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/793278
[patent_app_country] => US
[patent_app_date] => 2021-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22823
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793278
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793278 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Jan 25, 2021 | Pending |
Array
(
[id] => 18352319
[patent_doc_number] => 20230140430
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/792887
[patent_app_country] => US
[patent_app_date] => 2021-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19035
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 240
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792887
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/792887 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Jan 25, 2021 | Abandoned |
Array
(
[id] => 18324121
[patent_doc_number] => 20230122249
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/793162
[patent_app_country] => US
[patent_app_date] => 2021-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44361
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793162
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793162 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Jan 25, 2021 | Abandoned |
Array
(
[id] => 18336113
[patent_doc_number] => 20230128062
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/792561
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29443
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792561
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/792561 | Substituted oxaspiro[4.5]decanes as mor receptor agonists | Jan 14, 2021 | Issued |
Array
(
[id] => 20505871
[patent_doc_number] => 12540138
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-02-03
[patent_title] => Substituted oxaspiro[4.5]decanes as MOR receptor agonists
[patent_app_type] => utility
[patent_app_number] => 17/758899
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 15561
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 291
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17758899
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/758899 | Substituted oxaspiro[4.5]decanes as MOR receptor agonists | Jan 14, 2021 | Issued |
Array
(
[id] => 18413108
[patent_doc_number] => 11667641
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
[patent_app_type] => utility
[patent_app_number] => 17/143355
[patent_app_country] => US
[patent_app_date] => 2021-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 12086
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17143355
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/143355 | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile | Jan 6, 2021 | Issued |
Array
(
[id] => 18228672
[patent_doc_number] => 20230067666
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => METHOD FOR PREPARING COUMARIN COMPOUNDS SUBSTITUTED BY AMIDOALKYL AT 3-POSITION, THE PRODUCTS AND RELATED INTERMEDIATES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/758267
[patent_app_country] => US
[patent_app_date] => 2020-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13002
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17758267
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/758267 | METHOD FOR PREPARING COUMARIN COMPOUNDS SUBSTITUTED BY AMIDOALKYL AT 3-POSITION, THE PRODUCTS AND RELATED INTERMEDIATES THEREOF | Dec 29, 2020 | Abandoned |
Array
(
[id] => 18323570
[patent_doc_number] => 20230121698
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/788262
[patent_app_country] => US
[patent_app_date] => 2020-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58964
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -126
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788262
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/788262 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Dec 22, 2020 | Pending |
Array
(
[id] => 17067160
[patent_doc_number] => 20210269375
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => PEROVSKITE TYPE COMPOUND ABX3
[patent_app_type] => utility
[patent_app_number] => 17/132109
[patent_app_country] => US
[patent_app_date] => 2020-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17356
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17132109
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/132109 | Perovskite-type compounds of formula ABX3 | Dec 22, 2020 | Issued |
Array
(
[id] => 18212469
[patent_doc_number] => 20230058733
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => OGA INHIBITOR COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/757637
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10278
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17757637
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/757637 | OGA INHIBITOR COMPOUNDS | Dec 17, 2020 | Abandoned |
Array
(
[id] => 18225260
[patent_doc_number] => 20230064254
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT
[patent_app_type] => utility
[patent_app_number] => 17/786504
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16081
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786504
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | Dec 17, 2020 | Pending |
Array
(
[id] => 18916715
[patent_doc_number] => 11878985
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-23
[patent_title] => Substituted quinazolines as inhibitors of KRAS G12C
[patent_app_type] => utility
[patent_app_number] => 17/125955
[patent_app_country] => US
[patent_app_date] => 2020-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 57089
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 515
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125955
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/125955 | Substituted quinazolines as inhibitors of KRAS G12C | Dec 16, 2020 | Issued |